[
dcgi
]Latest from dcgi
'Compliant with norms': India to WHO on cough syrups and Gambia kids' deaths
All four cough syrup samples of Maiden Pharmacueticals tested by the government have been found compliant with norms, the national drugs controller has said in a recent letter to the WHO.
Updated on Dec 16, 2022 12:16 PM IST
Gambia deaths: India says WHO's info ‘inadequate’ to determine aetiology
On October 13, Rutendo Kuwana from the WHO had written to the DCGI and sought to know the progress with the investigation of the manufacturer of the four cough syrups - the Sonipat-based Maiden Pharmaceuticals.
Updated on Oct 15, 2022 11:54 PM IST
HT News Desk | Edited by Aniruddha Dhar, New Delhi
‘Diligently following protocol’: Maiden Pharma breaks silence on Gambia deaths
Maiden Pharma's director Vivek Goyal said on Saturday, said the company has been in the business for over three decades and their products are not sold in domestic market. The company said it has the requisite export approvals for the products that have come under the scanner of drug authorities.
Updated on Oct 09, 2022 05:04 AM IST
Soumya Pillai, New Delhi
Covovax granted EUA for children aged 7-12
The Drugs Controller General of India (DCGI), the country’s drugs regulator, on Tuesday granted emergency use authorisation (EUA) to India’s first indigenously developed mRNA vaccine against Covid-19 manufactured by Pune-based Gennova Biopharmaceuticals
Updated on Jun 29, 2022 01:34 AM IST
India clears Corbevax as a booster dose for adults
Corbevax can be administered as a Covid-19 booster dose for individuals aged 18 years and above, six months after they have been administered the second doses of Covishield or Covaxin, the DCGi said.
Published on Jun 04, 2022 11:56 PM IST
